The effect of empagliflozin on reduction of cardiovascular complication after PCI

Evaluation of the effect of empagliflozin administration on reduction of cardiovascular complication in diabetic patients after PCI

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210612051550N1

Enrollment

100

Registered

2021-06-20

Start date

2021-07-23

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: Intervention group: The patients will received empagliflozin (Abidi Pharmaceutical Company, Iran

10 mg or once daily) in addition to standard of care for 6 months after percutaneous coronary intervention (PCI). Intervention 2: Control group: The patients will received matching placebo, in additio

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with definitive diagnosis of diabetes mellitus type 2 (HbA1c= 6.8%) Consent to participate in the study

Exclusion criteria

Exclusion criteria: Diabetic ketoacidosis Urinary and genital infections Type 1 diabetes Severe liver failure Existence of malignancy and cancer eGFR 30 < ml/min

Design outcomes

Primary

Measure	Time frame
Major adverse cardiovascular events (MACE). Timepoint: During 6 month follow up after PCI. Method of measurement: Based on symptoms and clinical examinations, laboratory parameters and echocardiographic assessment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaad Fazeli

Ahvaz University of Medical Sciences

fazeli.s@ajums.ac.ir+98 61 3001 3374

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026